Carregant...

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

BACKGROUND: KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting (G12C)KRAS specifically, but therapeutic options for other mutant forms of KRAS are limited, largely because the c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., Holovanchuk, D., Pedersen, M., McLeary, R., Lorigan, P., Dhomen, N., Fisher, C., Banerji, U., Dean, E., Krebs, M.G., Gore, M., Larkin, J., Marais, R., Springer, C.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2021
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839839/
https://ncbi.nlm.nih.gov/pubmed/33130216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.annonc.2020.10.483
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!